Ekso Bionics Holdings, Inc. — Q2 2022 Form 10-Q
Issuer identity: The filing identifies the registrant as Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), which differs from the “Chronoscale Holdings Corp” company name in the request metadata. The quarter ended June 30, 2022; figures below are unaudited and in U.S. dollars unless stated otherwise.
Business context and reporting period
Ekso designs and sells exoskeleton products through its medical-device business, EksoHealth, and industrial business, EksoWorks. EksoHealth revenue is primarily from devices, service and support, and subscriptions; EksoWorks sells industrial exoskeletons and related products. The company reported FDA 510(k) clearance to market EksoNR for patients with multiple sclerosis and booked 17 EksoNR units in Q2.
Key financial results
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $3.465 million, up 57% year over year | $6.032 million, up 46% |
| Gross profit / margin | $1.641 million / 47%, versus $1.292 million / 58% | $2.850 million / 47%, versus $2.527 million / 61% |
| Operating expenses | $4.870 million, up 5% | $10.316 million, up 14% |
| Operating loss | $3.229 million, versus $3.348 million | $7.466 million, versus $6.487 million |
| Net loss | $2.978 million, versus $1.273 million | $7.598 million, versus $4.943 million |
| Net loss per share | $0.23, versus $0.10 basic | $0.59, versus $0.42 basic |
At June 30, cash was $31.912 million, including $2.0 million required to remain available under the bank-loan liquidity covenant; management described unrestricted cash as approximately $29.9 million. Working capital was $34.5 million, down from $40.9 million at December 31, 2021. Total liabilities were $8.791 million. The term loan had $2.0 million principal outstanding, due in August 2023; the company reported covenant compliance.
For the six months, operating cash use was $8.454 million, compared with $5.606 million a year earlier. Cash declined by $8.494 million to $31.912 million; there were no financing proceeds in the 2022 period, versus $38.712 million of financing cash inflow in 2021.
Changes versus the prior comparable period
- Revenue growth was led by EksoHealth, primarily higher EksoNR device sales, including a $1.1 million multi-unit customer deal. Q2 EksoHealth revenue rose about 73%; EksoWorks revenue fell about 32%.
- Despite higher gross profit dollars, gross margin fell 11 percentage points in Q2 and 14 points for the first half. Management cited increased service labor and materials, freight costs, and supply-related inventory costs.
- First-half operating expenses increased, including higher R&D spending and G&A costs associated in part with CEO stock compensation and former CEO severance. First-half net loss also reflected a larger unrealized foreign-exchange loss; the 2021 comparison included a $1.099 million PPP-loan forgiveness gain.
- At the end of Q2, Ekso ceased commercialization of its ZeroG support arm and related products. It may sell remaining parts and accessories, but does not expect material future ZeroG revenue.
Outlook, risks, and unusual items
Management said current unrestricted cash should fund operations beyond one year from issuance of the statements; it provided no specific revenue or earnings guidance. The company cited supply shortages, longer lead times, rising component and manufacturing costs, inflation, foreign-currency movements, COVID-19 uncertainty, long sales cycles, competition, regulatory and reimbursement requirements, and dependence on customer adoption. It reported $3.087 million of purchase obligations, generally expected to be paid within two years.
A $718,000 Q2 unrealized foreign-exchange loss contributed to the quarter’s results; the first-half loss was $972,000. The company’s warrant-liability remeasurement generated a $999,000 Q2 gain, a noncash item subject to valuation assumptions. A new San Rafael headquarters and manufacturing facility lease was signed in July 2022, with stated lease commitments of $1.455 million over 52 months. The CEO, President/COO, and interim CFO appointments followed executive departures during the period. Management stated disclosure controls were effective and reported no material changes to internal control over financial reporting; it identified no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm issuer identity and ticker: the supplied metadata names Chronoscale Holdings Corp, but the filing is for Ekso Bionics Holdings, Inc. (EKSO).
- Assess whether revenue growth, including the sizable multi-unit deal, can be sustained and whether customer concentration remains significant; three Q2 customers each represented at least 10% of revenue.
- Track gross-margin recovery, supply-chain costs, inventory levels, and operating cash burn against the company’s cash runway statements.
- Review ZeroG exit-related obligations, purchase commitments, the new facility lease, and the August 2023 loan maturity.
- Consider the sensitivity of reported earnings to foreign exchange and Level 3 warrant fair-value assumptions.